IFM Due

IFM Due, a subsidiary of IFM Therapeutics, is a biopharmaceutical company developing a suite of small-molecule antagonists and inhibitors targeting abnormal inflammatory responses of the innate immune system triggered by the cGAS-STING pathway, which is believed to contribute to a range of serious diseases. The company is advancing small-molecule, orally available drug candidates to address a broad spectrum of potential therapeutic indications, including rare, autoimmune, fibrotic, and neurodegenerative diseases.